APRE vs. FBRX, CLRB, PDSB, VTGN, ALLK, TLSA, LFVN, BYSI, AFMD, and VSTM
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Forte Biosciences (FBRX), Cellectar Biosciences (CLRB), PDS Biotechnology (PDSB), Vistagen Therapeutics (VTGN), Allakos (ALLK), Tiziana Life Sciences (TLSA), LifeVantage (LFVN), BeyondSpring (BYSI), Affimed (AFMD), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
Aprea Therapeutics (NASDAQ:APRE) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
Aprea Therapeutics presently has a consensus target price of $15.50, suggesting a potential upside of 244.44%. Forte Biosciences has a consensus target price of $3.38, suggesting a potential upside of 478.80%. Given Forte Biosciences' higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Aprea Therapeutics.
Aprea Therapeutics received 21 more outperform votes than Forte Biosciences when rated by MarketBeat users. However, 57.78% of users gave Forte Biosciences an outperform vote while only 52.81% of users gave Aprea Therapeutics an outperform vote.
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by insiders. Comparatively, 10.5% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Aprea Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.
In the previous week, Forte Biosciences had 4 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Forte Biosciences and 0 mentions for Aprea Therapeutics. Forte Biosciences' average media sentiment score of 0.97 beat Aprea Therapeutics' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media.
Forte Biosciences has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,317.82%. Aprea Therapeutics' return on equity of -56.78% beat Forte Biosciences' return on equity.
Aprea Therapeutics has higher revenue and earnings than Forte Biosciences. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Aprea Therapeutics and Forte Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
